Egfr as a clinical marker in glioblastomas and other gliomas
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
SAGE Publications Ltd
Abstract
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a member of the tyrosine kinase superfamily receptor. Gliomas are tumors originating from glial cells, which show a range of aggressiveness depending on grade and stage. Many EGFR gene alterations have been identified in gliomas, especially glioblastomas, including amplifications, deletions and single nucleotide polymorphisms (SNPs). Glioblastomas are discussed as a separate entity due to their high correlation with EGFR mutants and the reported association of the latter with survival and response to treatment in this glioma subgroup. This review is a comprehensive report of EGFR gene alterations and their relations with several clinical factors in glioblastomas and other gliomas. It covers all EGFR gene alterations including point mutations, SNPs, methylations, copy number variations and amplifications, assessed with regard to different clinical variables, including response to therapy and survival. This review also discusses the current prognostic status of EGFR in glioblastomas and other gliomas, and highlights gaps in previous studies. This serves as an update for the medical community about the role of EGFR gene alterations in gliomas and specifically glioblastomas, as a means for targeted treatment and prognosis. © The Author(s) 2017.
Description
Keywords
Epidermal growth factor receptor, Glioblastoma, Glioma, Prognosis, Tyrosine kinase inhibitor, Biomarkers, tumor, Dna copy number variations, Dna methylation, Humans, Mutation, Polymorphism, single nucleotide, Receptor, epidermal growth factor, Carboplatin, Cetuximab, Cisplatin, Epidermal growth factor receptor 2, Erlotinib, Gefitinib, Irinotecan, Phosphatidylinositol 3 kinase, Protein p53, Temozolomide, Tumor marker, Egfr protein, human, Angiogenesis, Autophagy, Copy number variation, Correlation analysis, Egfr gene, Fluorescence in situ hybridization, Gene, Gene amplification, Gene deletion, Gene mutation, Gene overexpression, Human, Immunohistochemistry, Nuclear magnetic resonance imaging, Overall survival, Phase 2 clinical trial (topic), Phase 3 clinical trial (topic), Point mutation, Progression free survival, Protein expression, Quality of life, Review, Rna splicing, Single nucleotide polymorphism, Survival analysis, Treatment response, Tumor growth, Upregulation, Genetics, Pathology